Lupin Limited has informed the Exchange regarding Change in Director(s) of the company.

Management Changes View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹1941.10

prior close

₹1942.20

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.4%+1.8% vs market

Pharmaceuticals peers, median of 151sector+0.0%+1.4% vs sector

On the reaction day the stock moved 1.8 pts more than Nifty Midcap 150 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.3

15m

-0.3

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4-0.4+1.8+0.0+1.4

Next day

+1.5-0.6+2.1-0.2+1.8

+1.1-0.6+1.7-0.6+1.7

-0.5-2.1+1.6-1.6+1.2

-2.1-3.3+1.2-2.7+0.6

-2.1-3.8+1.7-2.3+0.2

-2.6-1.9-0.6-1.4-1.2

15d

+5.1+0.0+5.1-0.4+5.5

+3.7+1.0+2.7+0.1+3.7

-0.0+1.9-1.9-2.6+2.6

+4.6+2.7+1.9-6.6+11.2

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin Limited's Board has approved the re-appointment of Mr. Mark D. McDade as an Independent Director for a second term of five consecutive years, effective from January 28, 2026 to January 27, 2031. The decision was made on the recommendation of the Nomination and Remuneration Committee and is subject to shareholder approval. Mr. McDade has over 40 years of experience in the biopharmaceutical industry, with expertise in corporate governance, leadership, healthcare, manufacturing, ESG, and M&A. He holds a Bachelor's degree from Dartmouth College and an MBA from Harvard Business School. He is not related to any existing Directors, KMPs, or Promoters of the company and is not debarred from holding directorship by any regulatory authority.

Likely market impact

This is a routine governance announcement with no material impact on the stock price. It signals board continuity, as the company retains an experienced independent director with strong pharma industry credentials for another five-year term.